SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oxford GlycoSciences Plc
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (434)4/3/2003 4:54:49 PM
From: nigel bates  Read Replies (1) of 469
 
Ill advised ?

All those nasty things we're saying about them must be touching a nerve.

Shares in Celltech (LSE: CCH.L - news - msgs) closed up 6.9 per cent at 296p on Thursday in London after the biotechnology firm's stock was upgraded to "buy" from "neutral" by UBS Warburg.
Analysts at the broker maintained a 360p price target on the shares.
UBS also said that Celltech's "ill-advised" bid for sector rival Oxford GlycoSciences looked set to be superseded by rival offers.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News